Bench2Bedside:
Chimeric Antigen Receptor (CAR) T-cell therapy has achieved remarkable clinical milestones, yet widespread adoption remains a challenge. How do you view the current landscape and its main limitations?

Haifeng Chen Ph.D., CEO of AAVivo, Inc.:
For decades, oncology researchers have chased therapies with greater and greater precision while also recognizing the need for treatments with the persistence of the immune system itself. The advent of CAR T-cell therapy has represented a major step towards this goal; we have seen patients with terminal, refractory B-cell malignancies walk out of hospitals in complete remission.

However, the current design of CAR-T therapy is a logistical masterpiece but a commercial and clinical bottleneck. We believe that the complexities inherent to these ex vivo (outside the body) cell therapies will continue to limit meaningful scale. In order to take these treatments to the next level, where they can truly impact patients across our healthcare system, we must democratize these technologies.

B2B:
Could you walk us through the specific technical and logistical challenges that make the traditional ex vivo “vein-to-vein” journey so fragile?

Chen:
Generating CAR-T therapies is a marvel of bio-engineering, but it is also incredibly fragile. The process begins with apheresis, where a patient’s T-cells are extracted, frozen, and shipped to a centralized manufacturing facility, often thousands of miles away. There, scientists reprogram the cells to recognize cancer before expanding them into the millions and shipping them back for re-infusion.

This “vein-to-vein” journey is fraught with challenges. Because many cancer patients are in a race against time, the three-to-four-week manufacturing process may be too long as they face rapidly progressing, late-stage cancers. Additionally, because these treatments are a customized “living drug” for one specific person, there are no economies of scale. Drugmakers are essentially running boutique shops in an industry that demands global supply chains.

B2B:
Beyond the logistics, the financial burden of these therapies is a frequent point of criticism. What is the true cost of the current model?

Chen:
The costs of custom treatments are prohibitive. The price tag for a single dose can exceed $400,000, and this does not include the intensive hospital stays required for lymphodepletion and patient monitoring. This economic model makes it incredibly difficult for health systems to sustainably adopt and scale these therapies to everyone who needs them.

B2B:
To solve these bottlenecks, you have advocated for an in vivo mindset. What does that paradigm shift look like in practice?

Chen:
Key to this effort will be a transition to an in vivo mindset, in which we stop treating the patient’s body as a passive recipient and start treating it as the world’s most sophisticated bioreactor. At AAVivo, we believe the future of patient-centered cell therapies that health systems can embrace won’t be in a cleanroom thousands of miles away from the patient. Rather, they will be hyper-local, targeting the generation of therapeutic cells directly within the patient’s own lymphatic system.

B2B:
Ultimately, how does shifting the focus from centralized manufacturing to in vivo engineering change the future of oncology?

Chen:
It shifts the entire paradigm from a manufacturing problem to an engineering solution. By moving the reprogramming process inside the body, we can bypass the costly, lengthy, and risky external manufacturing supply chain entirely. This approach has the potential to transform CAR-T from a rare, bespoke luxury into an accessible, off-the-shelf reality for patients worldwide.